Researchers at New York University's Department of Chemistry and NYU Langone Medical Center have developed a compound that blocks signaling from a protein implicated in many types of cancer. The compound is described in the latest issue of the journal Nature Chemical Biology. The researchers examined signaling by receptor tyrosine kinase (RTK). Abnormal RTK signaling is a major underlying cause of various developmental disorders and diseases, including many forms of cancer...
More...
More...